Pre-market ASX: HLS.AX Healius A$0.76 19 Feb 2026 earnings: Margin test

HLS.AX stock opens pre-market at A$0.76 after Healius Limited released earnings-related updates for 19 Feb 2026. The share price is down 4.40% from the prior close of A$0.80, with volume at 14,019,405.00 shares. Investors will watch margins in Pathology and Imaging after mixed top-line trends. We use Meyka AI-powered market analysis to link the results to valuation, cash flow metrics, and short-term price catalysts

Earnings snapshot: HLS.AX stock key figures

Healius reported an EPS of -0.78 and a trailing PE of -3.91, signalling continued net losses. Revenue per share stands at 1.85, while free cash flow per share is 0.31, supporting operational liquidity. Market capitalisation is A$591,798,267.00 and shares outstanding are 726,132,843.00, so earnings moves can alter market sentiment quickly.

Operational performance and segment trends

Pathology remains the largest segment, with 2,105 pathology sites providing scale advantages. Imaging has 134 sites and Day Hospitals have 11 sites, but margin pressure showed in the quarter. Receivables days are 39.35 and payables days are 51.69, reflecting working capital strain that affected the current ratio of 0.56.

Valuation, cash flow and balance sheet

Price to sales is 0.44 and price to book is 1.01, suggesting valuation near book value. Enterprise value is A$1,446,398,267.00 and net debt metrics show leverage risk with debt to equity at 1.55. Free cash flow yield is 0.38, which offers a counterpoint to weak profitability and supports near-term dividend capacity.

Technical view and trading signals for HLS.AX stock

Technically, RSI is 34.71, near oversold territory, and ADX at 27.29 shows a meaningful trend. The 50-day average is A$0.93 and the 200-day average is A$0.86, placing the price below both. Recent volume of 14,019,405.00 is well above the average 2,218,106.00, indicating high intraday interest.

Meyka grade & HLS.AX stock forecast

Meyka AI rates HLS.AX with a score out of 100: 68.81 (B) — HOLD. This grade factors in S&P 500 comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects monthly A$0.85 and quarterly A$0.92, reflecting a 11.84% and 21.05% implied upside versus the current price of A$0.76. Forecasts are model-based projections and not guarantees.

Risks and near-term catalysts for HLS.AX stock

Key risks include leverage with interest coverage near 0.00 and net debt to EBITDA of 9.28, which could limit strategic flexibility. Catalysts are margin improvement in Pathology, Day Hospital utilisation, and any positive guidance on cost control. Watch competitor benchmarking and sector YTD weakness of -6.01% for relative performance context.

Final Thoughts

Healius (HLS.AX) trades pre-market at A$0.76 after earnings-related updates on 19 Feb 2026. The company shows mixed cash flow strength with free cash flow per share 0.31 but negative EPS -0.78 and liability pressure with debt to equity 1.55. Meyka AI’s forecast model projects monthly A$0.85 and quarterly A$0.92, implying 11.84% and 21.05% upside respectively versus the current price. We present three price scenarios: conservative A$0.60 (implied downside -21.05%), base A$0.90 (implied upside 18.42%), and upside A$1.30 (implied upside 71.05%). The ASX Healthcare sector remains weak YTD -6.01%, which raises execution risk. Investors should weigh Healius’ scale in Pathology against high leverage and margin recovery timing. Sources and competitor context can be found on Investing.com and Meyka’s stock page for HLS.AX for deeper screening and real-time alerts. Forecasts are model-based projections and not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.